What is Lexicon Pharmaceuticals's market cap?

Lexicon Pharmaceuticals (LXRX) has a market capitalization of $990.6M and trades on NASDAQ.

What is Lexicon Pharmaceuticals's revenue and profitability?

Lexicon Pharmaceuticals generated $69.6M in trailing twelve-month revenue with a net loss of $26.1M, representing a net margin of -37.5%. Gross margin stands at 99.5%. These figures are based on the Q1 2026 filing.

Who are Lexicon Pharmaceuticals's competitors?

Lexicon Pharmaceuticals's key competitors include Eli Lilly, Vertex Pharmaceuticals, Pfizer, and others. These companies compete in similar markets and product categories.

Who does Lexicon Pharmaceuticals partner with?

Lexicon Pharmaceuticals's notable partners include Novo Nordisk, Viatris, Bristol-Myers Squibb, and others.

Where is Lexicon Pharmaceuticals headquartered?

Lexicon Pharmaceuticals is headquartered in United States of America and employs approximately 285 people. It has been publicly traded since 2000.

Lexicon Pharmaceuticals

LXRX

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule medicines for serious diseases.

Market cap

$990.56M+167%

Revenue$69.6M+123%

Net income-$26.1M+85.3%

EPS (diluted)-$0.07+86.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$21.1MBeat by $11.3M EPS-$0.00Beat by $0.04

Read the full report

Next report

Aug 5, 2026 (In 6 days)

Revenue estimate$4.0M

EPS estimate-$0.06

Financials

Q1 2026

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

Valuation & ratios

Valuation

See full

Market cap$990.56M+167%

Enterprise value$981.18M+141%

P/S14.2×+7.4×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Segments

By segment

See full

Reportable Segment$21.1M+1,572%

By product

See full

License$20.0M—

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

Vertex Pharmaceuticals$121.57B+2.7%

Cytokinetics$10.9B+150%

Mannkind$1.2B+1.4%

Lexicon Pharmaceuticals$990.6M+150%

PTH

Pelthos Therapeutics Inc.$95.9M+42.4%

By revenue growth

Cytokinetics+451%

Lexicon Pharmaceuticals+123%

Eli Lilly+47.4%

Mannkind+21.2%

Vertex Pharmaceuticals+10.1%

Merck & Co.+2.9%

Pfizer+1.4%

By net margin

Vertex Pharmaceuticals35.51%+42.7pp

Eli Lilly34.99%+12.3pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Mannkind9.32%-7.8pp

Lexicon Pharmaceuticals-37.46%+531pp

PTH

Pelthos Therapeutics Inc.-186.23%—

Cytokinetics-784.02%+2,417pp

Profile

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule medicines for serious diseases. The company utilizes a systematic, target biology-driven approach based on gene knockout technologies to identify and validate novel drug targets. Its core value proposition lies in its internal drug discovery engine and its ability to advance candidates through clinical development both independently and via strategic alliances.

Competitive position

Lexicon is a commercial-stage biotech with a specialized focus on SGLT inhibition and AAK1 targeting, competing against major pharmaceutical firms through a hybrid model of internal commercialization and strategic licensing.

GeographiesUnited States, Global

Customer segmentsWholesalers, Healthcare Providers, Pharmaceutical Companies

Business modelProduct-based, Licensing and Royalties, R&D Collaboration

SuppliersContract Manufacturing Organizations (CMOs), Raw material suppliers in Asia and Europe, Third-party logistics providers

CustomersMajor pharmaceutical wholesalers, Retail pharmacies, Hospitals, Government agencies, Specialist and primary care physicians

CountryUnited States of America

Listed2000

Employees285.0

CEOMichael S. Exton

SectorHealthcare

IndustryBiotechnology

Websitelexpharma.com

FilingsSEC EDGAR

Ask your AI about Lexicon Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's market cap?: Lexicon Pharmaceuticals (LXRX) has a market capitalization of $990.6M and trades on NASDAQ.
What is Lexicon Pharmaceuticals's revenue and profitability?: Lexicon Pharmaceuticals generated $69.6M in trailing twelve-month revenue with a net loss of $26.1M, representing a net margin of -37.5%. Gross margin stands at 99.5%. These figures are based on the Q1 2026 filing.
Who are Lexicon Pharmaceuticals's competitors?: Lexicon Pharmaceuticals's key competitors include Eli Lilly, Vertex Pharmaceuticals, Pfizer, and others. These companies compete in similar markets and product categories.
Who does Lexicon Pharmaceuticals partner with?: Lexicon Pharmaceuticals's notable partners include Novo Nordisk, Viatris, Bristol-Myers Squibb, and others.
Where is Lexicon Pharmaceuticals headquartered?: Lexicon Pharmaceuticals is headquartered in United States of America and employs approximately 285 people. It has been publicly traded since 2000.